Spanish competition authority CNMC has filed charges against the country’s leading pharmaceuticals, including Pfizer, S.L.U., Janssen-Cilag, S.A., Merck Sharp & Dohme de España S.A., Lilly, S.A., Sanofi-Aventis, S.A. and Novartis Farmacéutica, S.A. over alleged uncompetitive agreements. The companies are suspected of having set up distribution systems geared towards maintaining a double-pricing scheme, as well as agreements between the various laboratories.
The case dates back to a complaint presented by the European Association of Euro Pharmaceutical Companies (EAEPC) in 2007. In 2009 the CNMC’s predecessor, the CNC, decided to dismiss the case, having failed to find any evidence of competition law violations.
The decision by the former regulator was reversed in March 2016, with a resolution reopening the files and urging the CNMC to continue their investigations into the case.
Full Content: CNMC
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
CVS Health Explores Potential Breakup Amid Investor Pressure: Report
Oct 3, 2024 by
CPI
DirecTV Acquires Dish TV, Creating 20 Million-Subscriber Powerhouse
Oct 3, 2024 by
CPI
South Korea Fines Kakao Mobility $54.8 Million for Anti-Competitive Practices
Oct 3, 2024 by
CPI
Google Offers Settlement in India’s Antitrust Case Regarding Smart TVs
Oct 3, 2024 by
CPI
Attorney Challenges NCAA’s $2.78 Billion Settlement in Landmark Antitrust Cases
Oct 3, 2024 by
nhoch@pymnts.com
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh